Intraparenchymal haemorrhages as a primary outcome measure

Affiliations

¹ Department of Diagnostic Imaging, Foothills Medical Center, University of Calgary, Calgary, AB T2N2T9, Canada; Department of Clinical Neurosciences, Foothills Medical Center, University of Calgary, Calgary, AB T2N2T9, Canada. Electronic address: mgoyal@ucalgary.ca.
² Department of Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
³ Department of Clinical Neurosciences, Foothills Medical Center, University of Calgary, Calgary, AB T2N2T9, Canada.
⁴ Department of Diagnostic Imaging, Foothills Medical Center, University of Calgary, Calgary, AB T2N2T9, Canada.

Comment

Mayank Goyal et al. Lancet Neurol. 2021 Aug.

. 2021 Aug;20(8):595.

doi: 10.1016/S1474-4422(21)00183-6.

¹ Department of Diagnostic Imaging, Foothills Medical Center, University of Calgary, Calgary, AB T2N2T9, Canada; Department of Clinical Neurosciences, Foothills Medical Center, University of Calgary, Calgary, AB T2N2T9, Canada. Electronic address: mgoyal@ucalgary.ca.
² Department of Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
³ Department of Clinical Neurosciences, Foothills Medical Center, University of Calgary, Calgary, AB T2N2T9, Canada.
⁴ Department of Diagnostic Imaging, Foothills Medical Center, University of Calgary, Calgary, AB T2N2T9, Canada.

No abstract available

Conflict of interest statement

We declare no competing interests.

Intraparenchymal haemorrhages as a primary outcome measure - Authors' reply.
Maïer B, Desilles JP, Mazighi M; BP-TARGET Investigators. Maïer B, et al. Lancet Neurol. 2021 Aug;20(8):595-596. doi: 10.1016/S1474-4422(21)00184-8. Lancet Neurol. 2021. PMID: 34302779 No abstract available.

Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
Mazighi M, Richard S, Lapergue B, Sibon I, Gory B, Berge J, Consoli A, Labreuche J, Olivot JM, Broderick J, Duhamel A, Touze E, Qureshi AI, Yavchitz A, Escalard S, Desilles JP, Redjem H, Smajda S, Fahed R, Hébert S, Maïer B, Delvoye F, Boursin P, Maacha MB, Obadia M, Sabben C, Blanc R, Savatovsky J, Piotin M; BP-TARGET investigators. Mazighi M, et al. Lancet Neurol. 2021 Apr;20(4):265-274. doi: 10.1016/S1474-4422(20)30483-X. Epub 2021 Feb 26. Lancet Neurol. 2021. PMID: 33647246 Clinical Trial.